X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2022-09-22 | MEDP | Medpace Holdings, Inc. | Medpace Investors, LLC | 10% | P - Purchase | $154.59 | +57,426 | 6,483,019 | +1% | +$8,877,485 | ||||||
2022-09-22 | MEDP | Medpace Holdings, Inc. | Troendle August J. | CEO, 10% | P - Purchase | $154.59 | +57,426 | 7,289,662 | +1% | +$8,877,485 | ||||||
| M | 2022-09-20 | MEDP | Medpace Holdings, Inc. | Troendle August J. | CEO, 10% | P - Purchase | $158.39 | +188,238 | 7,232,236 | +3% | +$29,814,076 | |||||
| M | 2022-09-20 | MEDP | Medpace Holdings, Inc. | Medpace Investors, LLC | 10% | P - Purchase | $158.39 | +188,238 | 6,425,593 | +3% | +$29,814,076 | |||||
| M | 2022-09-16 | MEDP | Medpace Holdings, Inc. | Medpace Investors, LLC | 10% | P - Purchase | $151.92 | +156,635 | 6,237,355 | +3% | +$23,796,527 | |||||
| M | 2022-09-16 | MEDP | Medpace Holdings, Inc. | Troendle August J. | CEO, 10% | P - Purchase | $151.92 | +156,635 | 7,043,998 | +2% | +$23,796,527 | |||||
2022-09-15 | NOTV | Inotiv, Inc. | Garrett Michael | Chief Commercial Officer | P - Purchase | $23.06 | +1,000 | 2,000 | +100% | +$23,058 | ||||||
2022-09-16 | AIKI | Aikido Pharma Inc. | Wool Kyle Michael | Dir | P - Purchase | $6.54 | +3,559 | 230,281 | +2% | +$23,287 | ||||||
| M | 2022-09-14 | MEDP | Medpace Holdings, Inc. | Troendle August J. | CEO, 10% | P - Purchase | $152.89 | +125,032 | 6,887,363 | +2% | +$19,115,517 | |||||
| M | 2022-09-14 | MEDP | Medpace Holdings, Inc. | Medpace Investors, LLC | 10% | P - Purchase | $152.89 | +125,032 | 6,080,720 | +2% | +$19,115,517 | |||||
2022-09-14 | NRC | National Research Corp | Amandla Mk Trust | 10% | S - Sale | $38.59 | -100,000 | 5,585,594 | -2% | -$3,858,900 | ||||||
2022-09-14 | AIKI | Aikido Pharma Inc. | Yu Soo | Dir | P - Purchase | $6.12 | +1,477 | 83,701 | +2% | +$9,033 | ||||||
2022-09-14 | AIKI | Aikido Pharma Inc. | Wool Kyle Michael | Dir | P - Purchase | $6.12 | +2,953 | 284,566 | +1% | +$18,061 | ||||||
2022-09-13 | AIKI | Aikido Pharma Inc. | Yu Soo | Dir | P - Purchase | $6.32 | +29,329 | 82,224 | +55% | +$185,447 | ||||||
2022-09-13 | AIKI | Aikido Pharma Inc. | Hayes Anthony | CEO | P - Purchase | $6.32 | +24,957 | 147,181 | +20% | +$157,803 | ||||||
2022-09-13 | AIKI | Aikido Pharma Inc. | Wool Kyle Michael | Dir | P - Purchase | $6.32 | +23,712 | 140,068 | +20% | +$149,931 | ||||||
| M | 2022-09-12 | MEDP | Medpace Holdings, Inc. | Troendle August J. | CEO, 10% | P - Purchase | $162.35 | +125,031 | 6,762,331 | +2% | +$20,298,778 | |||||
| M | 2022-09-12 | MEDP | Medpace Holdings, Inc. | Medpace Investors, LLC | 10% | P - Purchase | $162.35 | +125,031 | 5,955,688 | +2% | +$20,298,778 | |||||
2022-09-12 | AIKI | Aikido Pharma Inc. | Yu Soo | Dir | P - Purchase | $6.33 | +44,895 | 52,895 | +561% | +$283,961 | ||||||
2022-09-12 | AIKI | Aikido Pharma Inc. | Wool Kyle Michael | Dir | P - Purchase | $6.33 | +36,298 | 116,356 | +45% | +$229,585 | ||||||
2022-09-12 | AIKI | Aikido Pharma Inc. | Hayes Anthony | CEO | P - Purchase | $6.33 | +38,208 | 122,224 | +45% | +$241,666 | ||||||
2022-09-09 | NOTV | Inotiv, Inc. | Beattie John Gregory | COO | P - Purchase | $22.34 | +8,900 | 51,694 | +21% | +$198,826 | ||||||
| M | 2022-09-08 | MEDP | Medpace Holdings, Inc. | Troendle August J. | CEO, 10% | P - Purchase | $160.99 | +113,114 | 6,637,300 | +2% | +$18,210,223 | |||||
| M | 2022-09-08 | MEDP | Medpace Holdings, Inc. | Medpace Investors, LLC | 10% | P - Purchase | $160.99 | +113,114 | 5,830,657 | +2% | +$18,210,223 | |||||
| M | 2022-09-06 | MEDP | Medpace Holdings, Inc. | Medpace Investors, LLC | 10% | P - Purchase | $149.16 | +113,114 | 5,717,543 | +2% | +$16,871,519 | |||||
| M | 2022-09-06 | MEDP | Medpace Holdings, Inc. | Troendle August J. | CEO, 10% | P - Purchase | $149.16 | +113,114 | 6,524,186 | +2% | +$16,871,519 | |||||
2022-09-02 | ZY | Zymergen Inc. | Singh Enakshi | CFO | S - Sale | $2.21 | -3,928 | 466,027 | -1% | -$8,681 | ||||||
2022-09-02 | ZY | Zymergen Inc. | Kim Mina | GC | S - Sale | $2.21 | -3,410 | 298,427 | -1% | -$7,536 | ||||||
2022-09-02 | ZY | Zymergen Inc. | Serber Zachariah | Chief Science Officer | S - Sale | $2.21 | -3,268 | 2,631,685 | 0% | -$7,222 | ||||||
| M | 2022-09-01 | MEDP | Medpace Holdings, Inc. | Medpace Investors, LLC | 10% | P - Purchase | $144.77 | +90,790 | 5,604,429 | +2% | +$13,143,379 | |||||
| M | 2022-09-01 | MEDP | Medpace Holdings, Inc. | Troendle August J. | CEO, 10% | P - Purchase | $144.77 | +90,790 | 6,411,072 | +1% | +$13,143,379 | |||||
2022-08-30 | ZY | Zymergen Inc. | Singh Enakshi | CFO | S - Sale | $2.27 | -15,365 | 469,955 | -3% | -$34,946 | ||||||
2022-08-11 | ZY | Zymergen Inc. | Serber Zachariah | Chief Science Officer | S - Sale | $3.91 | -5,435 | 2,634,953 | 0% | -$21,251 | ||||||
2022-08-05 | CRL | Charles River Laboratories International, Inc. | Laplume Joseph W | EVP, Corp Strategy, Develop | S - Sale | $226.13 | -200 | 20,766 | -1% | -$45,227 | ||||||
2022-08-02 | ZY | Zymergen Inc. | Serber Zachariah | Chief Science Officer | S - Sale | $2.61 | -2,966 | 2,640,388 | 0% | -$7,749 | ||||||
2022-08-02 | ZY | Zymergen Inc. | Kim Mina | GC | S - Sale | $2.61 | -3,094 | 301,837 | -1% | -$8,083 | ||||||
2022-07-28 | SYNH | Syneos Health, Inc. | Brooks Michael Lee | COO | S - Sale | $78.00 | -1,502 | 56,894 | -3% | -$117,156 | ||||||
2022-07-22 | INCY | Incyte Corp | Tray Thomas | Principal Accounting Officer | S - Sale | $83.13 | -1,564 | 17,702 | -8% | -$130,015 | ||||||
2022-07-21 | SYNH | Syneos Health, Inc. | Brooks Michael Lee | COO | S - Sale | $76.00 | -1,502 | 58,396 | -3% | -$114,152 | ||||||
2022-07-20 | SYNH | Syneos Health, Inc. | Olefson Jonathan | GC, Corp Secty | S - Sale | $75.00 | -2,215 | 25,292 | -8% | -$166,125 | ||||||
2022-07-19 | SYNH | Syneos Health, Inc. | Brooks Michael Lee | COO | S - Sale | $74.00 | -1,502 | 59,898 | -2% | -$111,148 | ||||||
2022-07-18 | SYNH | Syneos Health, Inc. | Keefe Michelle | CEO | S - Sale | $72.81 | -8,333 | 71,266 | -10% | -$606,726 | ||||||
2022-07-18 | SYNH | Syneos Health, Inc. | Meggs Jason M. | CFO | S - Sale | $72.81 | -7,500 | 54,736 | -12% | -$546,075 | ||||||
2022-07-18 | MEDP | Medpace Holdings, Inc. | Troendle August J. | CEO, 10% | P - Purchase | $145.00 | +8,330 | 6,320,282 | 0% | +$1,207,850 | ||||||
2022-07-18 | MEDP | Medpace Holdings, Inc. | Medpace Investors, LLC | 10% | P - Purchase | $145.00 | +8,330 | 5,513,639 | 0% | +$1,207,850 | ||||||
2022-07-14 | MEDP | Medpace Holdings, Inc. | Troendle August J. | CEO, 10% | P - Purchase | $144.59 | +22,290 | 6,311,952 | 0% | +$3,222,911 | ||||||
2022-07-14 | MEDP | Medpace Holdings, Inc. | Medpace Investors, LLC | 10% | P - Purchase | $144.59 | +22,290 | 5,505,309 | 0% | +$3,222,911 | ||||||
2022-07-08 | SYNH | Syneos Health, Inc. | Kralowetz Donna Hildebrand | EVP, Chief Accounting Officer | S - Sale | $73.16 | -1,149 | 6,805 | -14% | -$84,061 | ||||||
2022-07-07 | INCY | Incyte Corp | Iyengar Vijay K | EVP, GMAPPS | S - Sale | $79.38 | -5,787 | 40,313 | -13% | -$459,372 | ||||||
2022-07-07 | INCY | Incyte Corp | Flannelly Barry P | EVP, GM US | S - Sale | $79.38 | -2,873 | 72,674 | -4% | -$228,059 | ||||||
2022-07-05 | ZY | Zymergen Inc. | Serber Zachariah | Chief Science Officer | S - Sale | $1.32 | -2,797 | 2,643,354 | 0% | -$3,698 | ||||||
2022-07-05 | ZY | Zymergen Inc. | Kim Mina | GC | S - Sale | $1.32 | -2,924 | 304,931 | -1% | -$3,866 | ||||||
2022-07-01 | MXCT | Maxcyte, Inc. | Casdin Partners Master Fund, L.P. | 10% | S - Sale | $4.30 | -3,235,548 | 10,735,786 | -23% | -$13,912,856 | ||||||
2022-06-09 | NRC | National Research Corp | Amandla Mk Trust | 10% | S - Sale | $36.00 | -246,378 | 5,685,594 | -4% | -$8,869,608 | ||||||
2022-06-02 | ZY | Zymergen Inc. | Kim Mina | GC | S - Sale | $1.68 | -2,939 | 307,855 | -1% | -$4,930 | ||||||
2022-06-02 | ZY | Zymergen Inc. | Serber Zachariah | Chief Science Officer | S - Sale | $1.68 | -2,812 | 2,646,151 | 0% | -$4,717 | ||||||
2022-06-03 | SBFM | Sunshine Biopharma, Inc | Sebaaly Camille | CFO, Secretary | P - Purchase | $1.22 | +25,000 | 144,465 | +21% | +$30,500 | ||||||
2022-05-31 | SYNH | Syneos Health, Inc. | Monaghan Matthew E. | Dir | S - Sale | $74.35 | -200 | 19,777 | -1% | -$14,870 | ||||||
| D | 2022-05-10 | MLCT | Malachite Innovations, Inc. | Loconti Joseph E. | 10% | P - Purchase | $0.15 | +6,666,667 | 20,053,730 | +50% | +$1,000,000 | |||||
2022-05-09 | CRL | Charles River Laboratories International, Inc. | Massaro George | Dir | S - Sale | $230.96 | -178 | 4,677 | -4% | -$41,110 | ||||||
2022-05-06 | BUDZ | Weed, Inc. | Breen Nicole M | Secretary, Treasurer, 10% | S - Sale | $0.19 | -30,000 | 21,035,584 | 0% | -$5,724 | ||||||
2022-05-02 | ZY | Zymergen Inc. | Serber Zachariah | Chief Science Officer | S - Sale | $1.79 | -3,082 | 2,648,963 | 0% | -$5,518 | ||||||
2022-05-02 | ZY | Zymergen Inc. | Kim Mina | GC | S - Sale | $1.79 | -3,206 | 310,794 | -1% | -$5,740 | ||||||
2022-04-26 | BUDZ | Weed, Inc. | Breen Nicole M | Secretary, Treasurer, 10% | S - Sale | $0.21 | -20,000 | 21,065,584 | 0% | -$4,224 | ||||||
2022-04-21 | NRC | National Research Corp | Amandla Mk Trust | 10% | S - Sale | $39.87 | -100 | 5,931,972 | 0% | -$3,987 | ||||||
| M | 2022-04-19 | NRC | National Research Corp | Amandla Mk Trust | 10% | S - Sale | $39.91 | -3,522 | 5,932,072 | 0% | -$140,557 | |||||
2022-04-18 | BUDZ | Weed, Inc. | Breen Nicole M | Secretary, Treasurer, 10% | S - Sale | $0.24 | -35,000 | 21,085,584 | 0% | -$8,225 | ||||||
| D | 2022-04-08 | INCY | Incyte Corp | Flannelly Barry P | EVP, GM US | S - Sale+OE | $83.49 | -43,993 | 65,163 | -40% | -$3,672,887 | |||||
| M | 2022-04-07 | NRC | National Research Corp | Amandla Mk Trust | 10% | S - Sale | $40.37 | -2,400 | 5,935,594 | 0% | -$96,881 | |||||
2022-04-06 | NRC | National Research Corp | Amandla Mk Trust | 10% | S - Sale | $40.71 | -8,137 | 5,937,994 | 0% | -$331,252 | ||||||
| M | 2022-04-04 | NRC | National Research Corp | Amandla Mk Trust | 10% | S - Sale | $40.32 | -8,127 | 5,946,131 | 0% | -$327,661 | |||||
2022-04-01 | ZY | Zymergen Inc. | Kimball Aaron | CTO | S - Sale | $2.87 | -32,639 | 712,644 | -4% | -$93,551 | ||||||
2022-03-28 | BUDZ | Weed, Inc. | Breen Nicole M | Secretary, Treasurer, 10% | S - Sale | $0.28 | -20,000 | 21,120,584 | 0% | -$5,600 | ||||||
2022-03-25 | BUDZ | Weed, Inc. | Breen Nicole M | Secretary, Treasurer, 10% | S - Sale | $0.25 | -45,000 | 21,140,584 | 0% | -$11,283 | ||||||
2022-03-15 | NOTV | Inotiv, Inc. | Harkness James | COO, RMS | P - Purchase | $19.65 | +38,968 | 38,968 | New | +$765,637 | ||||||
| DM | 2022-03-08 | INCY | Incyte Corp | Baker Bros. Advisors LP | Dir, 10% | P - Purchase | $72.24 | +389,080 | 34,012,428 | +1% | +$28,107,770 | |||||
2022-03-09 | BUDZ | Weed, Inc. | Breen Nicole M | Secretary, Treasurer, 10% | S - Sale | $0.19 | -15,000 | 21,185,584 | 0% | -$2,850 | ||||||
| D | 2022-03-03 | CRL | Charles River Laboratories International, Inc. | Smith David Ross | Corporate EVP, CFO | S - Sale+OE | $282.53 | -8,965 | 25,819 | -26% | -$2,532,921 | |||||
2022-03-01 | ZY | Zymergen Inc. | Kimball Aaron | CTO | S - Sale | $3.81 | -25,000 | 745,283 | -3% | -$95,345 | ||||||
2022-02-28 | BUDZ | Weed, Inc. | Breen Nicole M | Secretary, Treasurer, 10% | S - Sale | $0.19 | -18,449 | 21,200,584 | 0% | -$3,567 | ||||||
2022-02-25 | BUDZ | Weed, Inc. | Breen Nicole M | Secretary, Treasurer, 10% | S - Sale | $0.20 | -25,000 | 21,219,033 | 0% | -$5,000 | ||||||
| D | 2022-02-23 | CRL | Charles River Laboratories International, Inc. | Foster James C | COB, Pres, CEO | S - Sale+OE | $287.83 | -20,296 | 253,941 | -7% | -$5,841,869 | |||||
2022-02-23 | CRL | Charles River Laboratories International, Inc. | Laplume Joseph W | EVP, Corp Strategy, Develop | S - Sale | $292.75 | -395 | 19,852 | -2% | -$115,636 | ||||||
2022-02-23 | BUDZ | Weed, Inc. | Breen Nicole M | Secretary, Treasurer, 10% | S - Sale | $0.20 | -25,000 | 21,244,033 | 0% | -$5,003 | ||||||
2022-02-22 | ZY | Zymergen Inc. | Serber Zachariah | Chief Science Officer | S - Sale | $3.91 | -1,424 | 2,453,491 | 0% | -$5,568 | ||||||
2022-02-22 | NOTV | Inotiv, Inc. | Downing Philip A | SVP, Preclinical Srvcs. | P - Purchase | $23.97 | +2,000 | 42,195 | +5% | +$47,946 | ||||||
| D | 2022-02-22 | CRL | Charles River Laboratories International, Inc. | Foster James C | COB, Pres, CEO | S - Sale+OE | $288.67 | -17,436 | 253,941 | -6% | -$5,033,328 | |||||
| DM | 2022-02-18 | CRL | Charles River Laboratories International, Inc. | Laplume Joseph W | EVP, Corp Strategy, Develop | S - Sale+OE | $291.55 | -1,539 | 20,247 | -7% | -$448,698 | |||||
| M | 2022-02-18 | CRL | Charles River Laboratories International, Inc. | Wallman Richard F | Dir | S - Sale | $292.84 | -7,200 | 17,679 | -29% | -$2,108,413 | |||||
| M | 2022-02-17 | INCY | Incyte Corp | Baker Bros. Advisors LP | Dir, 10% | P - Purchase | $67.96 | +525,804 | 33,632,977 | +2% | +$35,734,890 | |||||
2022-02-17 | MEDP | Medpace Holdings, Inc. | Davenport Fred B Jr | Dir | P - Purchase | $145.80 | +500 | 2,000 | +33% | +$72,900 | ||||||
2022-02-18 | NOTV | Inotiv, Inc. | Taylor Beth | VP- Finance, CFO | P - Purchase | $23.07 | +5,000 | 83,875 | +6% | +$115,358 | ||||||
| M | 2022-02-17 | NOTV | Inotiv, Inc. | Davis Gregory Cole | Dir | P - Purchase | $22.39 | +5,000 | 37,683 | +15% | +$111,928 | |||||
2022-02-18 | NOTV | Inotiv, Inc. | Garrett Michael | Chief Commercial Officer | P - Purchase | $23.50 | +1,000 | 1,000 | New | +$23,500 | ||||||
2022-02-18 | NOTV | Inotiv, Inc. | Pitchford William D | CHRO | P - Purchase | $21.12 | +3,500 | 76,174 | +5% | +$73,920 | ||||||
| M | 2022-02-16 | NOTV | Inotiv, Inc. | Beattie John Gregory | COO | P - Purchase | $22.71 | +11,400 | 42,794 | +36% | +$258,871 | |||||
2022-02-17 | NOTV | Inotiv, Inc. | Leasure Robert Jr. | Pres, CEO | P - Purchase | $23.03 | +5,000 | 290,216 | +2% | +$115,131 | ||||||
2022-02-17 | NOTV | Inotiv, Inc. | Sagartz John E | Chief Strategy Officer | P - Purchase | $19.95 | +2,506 | 681,030 | 0% | +$49,999 | ||||||
2021-09-23 | IQV | Iqvia Holdings Inc. | Bruehlman Ronald E | See Remarks | P - Purchase | $262.82 | +4 | 38,104 | 0% | +$1,051 | ||||||
2021-10-25 | IQV | Iqvia Holdings Inc. | Bruehlman Ronald E | See Remarks | S - Sale | $256.93 | -4 | 38,104 | 0% | -$1,028 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |